Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

 
      
    

다른 언어로 보기

뉴스

###

233,367 회사 소개

  • 검색 횟수: (지난 7일간: 63) (지난 30일간: 272) (게재 이후: 28274) 

회사 데이터

    사령부
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • 전화
  • +61-2-9499-8010 
  • 팩시밀리
  • +61-2-9499-8020 
  • 주요 분야
  • 제약 / 의료 
  • 주요 기업
  • Biotechnology 
  • 홈페이지
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

더 많은 뉴스 보기

  • 2024/04/08: Proposed issue of securities - RGS*
  • 2024/04/08: Ceasing to be a substantial holder - Kirman 2*
  • 2024/04/08: Ceasing to be a substantial holder - Lee*
  • 2024/04/08: Ceasing to be a substantial holder - Vesey*
  • 2024/04/08: Change of Company Name and ASX Code*
  • 2024/04/05: Cambium Bio Raises A$3.48 Million in Strategic Placement*
  • 2024/04/05: Final Director's Interest Notice - Leo Lee*
  • 2024/04/05: Director Resignation - Leo Lee*
  • 2024/04/05: Notice of initial substantial holder*
  • 2024/04/05: Initial Director's Interest Notice - Waller*
*refer to company website

소셜 미디어